Probable Cerebral Amyloid Angiopathy–Related Inflammation Associated With Sitravatinib
A Case Report
Abstract
Background and Objectives
We present the case of a 67-year-old man who developed encephalopathy, headaches, and seizure activity after initiating treatment with the novel tyrosine kinase inhibitor, sitravatinib.
Methods
The patient was identified in routine clinical practice.
Results
Brain MRI revealed lobar microhemorrhages and bihemispheric vasogenic edema. The patient met the criteria for probable cerebral amyloid angiopathy–related inflammation (CAA-ri) and responded favorably to high-dose methylprednisolone.
Discussion
This report of neurologic autoimmunity in a patient receiving sitravatinib opens new lines of inquiry into the pathophysiology of CAA-ri. We emphasize the importance of early recognition and treatment of CAA-ri among patients receiving immunomodulatory chemotherapy.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Auriel E, Charidimou A, Gurol ME, et al. Validation of clinicoradiological criteria for the diagnosis of cerebral amyloid angiopathy–related inflammation. JAMA Neurol. 2016;73(2):197.
2.
Du W, Huang H, Sorrelle N, Brekken RA. Sitravatinib potentiates immune checkpoint blockade in refractory cancer models. JCI Insight. 2018;3(21):e124184.
3.
Wium M, Paccez JD, Zerbini LF. The dual role of TAM receptors in autoimmune diseases and cancer: an overview. Cells. 2018;7(10):166.
4.
Szilveszter KP, Németh T, Mócsai A. Tyrosine kinases in autoimmune and inflammatory skin diseases. Front Immunol. 2019;10:1862.
5.
Kerkemeyer KLS, Lai FYX, Mar A. Lichen planus pemphigoides during therapy with tislelizumab and sitravatinib in a patient with metastatic lung cancer. Australas J Dermatol. 2020;61(2):180-182.
6.
Wu J-J, Yao M, Ni J. Cerebral amyloid angiopathy-related inflammation: current status and future implications. Chin Med J (Engl). 2021;134(6):646-654.
7.
Lasocki A, Kee D. Clinical and radiological evolution of cerebral amyloid angiopathy-related inflammation in the context of anti-PD-1 immunotherapy. Melanoma Res. 2020;30(6):608-612.
Information & Authors
Information
Published In
Neurology® Clinical Practice
Volume 12 • Number 2 • April 2022
Pages: e4-e6
Copyright
© 2022 American Academy of Neurology.
Publication History
Received: October 12, 2021
Accepted: February 2, 2022
Published online: March 1, 2022
Published in print: April 2022
Disclosure
The authors report no disclosures relevant to the manuscript. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/cp.
Study Funding
No targeted funding reported.
Authors
Metrics & Citations
Metrics
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Sitravatinib, Reactions Weekly, 1914, 1, (399-399), (2022).https://doi.org/10.1007/s40278-022-18985-2
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.